Background/Aims: To estimate the prevalence of diagnosed endometriosis (DE) in women in the United States and assess the associated symptomatic burden. Methods: An online, cross-sectional survey of women aged 18-49 years was conducted from August 6, 2012, through November 14, 2012. Survey data (weighted by age, race, education, income, geographical distribution, and propensity score) were used to estimate the prevalence and symptomatic burden of DE in women in the United States. Weighted logistic regressions were used to assess differences in symptom burden between women with and without endometriosis. Results: The prevalence of DE was estimated at 6.1% (2,922 of 48,020 women surveyed); 52.7% of women were 18-29 years of age when they were diagnosed with endometriosis. Most (86.2%) women experienced symptoms before diagnosis. More women with (vs. without) DE had menstrual pelvic pain/cramping (52.7 vs. 45.2%), non-menstrual pelvic pain/cramping (36.7 vs. 14.3%), infertility (11.6 vs. 3.4%), and dyspareunia (29.5 vs. 13.4%). Women with endometriosis were also more likely to report severe symptoms (OR (95% CI) 2.7 (2.3-3.1) for menstrual pelvic pain/cramping, 2.2 (1.7-2.9) for non-menstrual pelvic pain/cramping, and 2.4 (1.8-3.2) for dyspareunia). Conclusion: The prevalence of DE among US women is notable, and affected women experience a substantial symptom burden.

Keywords:
Endometriosis, Prevalence, Symptoms, Cross-sectional survey
1.
Bulun SE: Endometriosis. N Engl J Med 2009;360:268-279.
2.
Prescott J, Farland LV, Tobias DK, et al: A prospective cohort study of endometriosis and subsequent risk of infertility. Hum Reprod 2016;31:1475-1482.
3.
Ballard KD, Seaman HE, de Vries CS, Wright JT: Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study - part 1. BJOG 2008;115:1382-1391.
4.
Wheeler JM: Epidemiology of endometriosis-associated infertility. J Reprod Med 1989;34:41-46.
5.
Giudice LC, Kao LC: Endometriosis. Lancet 2004;364:1789-1799.
6.
Allaire C: Endometriosis and infertility: a review. J Reprod Med 2006;51:164-168.
7.
Guo SW, Wang Y: Sources of heterogeneities in estimating the prevalence of endometriosis in infertile and previously fertile women. Fertil Steril 2006;86:1584-1595.
8.
Eskenazi B, Warner ML: Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24:235-258.
9.
Wheeler JM: Epidemiology and prevalence of endometriosis. Infertility Reprod Med Clin North Am 1992;3:545-549.
10.
Rawson JM: Prevalence of endometriosis in asymptomatic women. J Reprod Med 1991;36:513-515.
11.
Khong SY, Lam A, Luscombe G: Is the 30-item Endometriosis Health Profile (EHP-30) suitable as a self-report health status instrument for clinical trials? Fertil Steril 2010;94:1928-1932.
12.
Simoens S, Meuleman C, D'Hooghe T: Non-health-care costs associated with endometriosis. Hum Reprod 2011;26:2363-2367.
13.
Ballard KD, Seaman HE, de Vries CS, Wright JT: Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study - part 1. BJOG 2008;115:1382-1391.
14.
Mirkin D, Murphy-Barron C, Iwasaki K: Actuarial analysis of private payer administrative claims data for women with endometriosis. J Manag Care Pharm 2007;13:262-272.
15.
Bernuit D, Ebert AD, Halis G, et al: Female perspectives on endometriosis: findings from the uterine bleeding and pain women's research study. J Endometr 2011;3:73-85.
16.
Work SS, Colamonico JA, Bradley WG, Kaye RE: Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Adv Ther 2011;28:586-601.
17.
Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ: Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes 2010;3:120-127.
18.
Stewart EA, Nicholson WK, Bradley L, Borah BJ: The burden of uterine fibroids for African-American women: results of a national survey. J Womens Health (Larchmt) 2013;22:807-816.
19.
Borah BJ, Nicholson WK, Bradley L, Stewart EA: The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol 2013;209:319.e1-e20.
20.
Schonlau M, Zapert K, Simon LP, et al: A comparison between responses from a propensity-weighted web survey and an identical RDD survey. Soc Sci Comput Rev 2004;22:128-138.
21.
Current Population Survey (CPS), March 2011. http://www.census.gov/cps/ (accessed October 29, 2014).
22.
De Graaff AA, D'Hooghe TM, Dunselman GA, et al: The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. Hum Reprod 2013;28:2677-2685.
23.
Rao JNK, Scott AJ: The analysis of categorical data from complex sample surveys: chi-squared tests for goodness of fit and independence in two-way tables. J Am Stat Assoc 1981;76:221-230.
24.
Simoens S, Dunselman G, Dirksen C, et al: The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod 2012;27:1292-1299.
25.
Nnoaham KE, Hummelshoj L, Webster P, et al; World Endometriosis Research Foundation Global Study of Women's Health Consortium: Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril 2011;96:366-373.
26.
Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL: Economic burden of endometriosis. Fertil Steril 2006;86:1561-1572.
27.
Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R: Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004;82:878-884.
28.
Winkel CA: Evaluation and management of women with endometriosis. Obstet Gynecol 2003;102:397-408.
29.
Klein S, D'Hooghe T, Meuleman C, Dirksen C, Dunselman G, Simoens S: What is the societal burden of endometriosis-associated symptoms? A prospective Belgian study. Reprod Biomed Online 2014;28:116-124.
30.
Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P: High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod 2002;17:2715-2724.
31.
Hadfield R, Mardon H, Barlow D, Kennedy S: Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK. Hum Reprod 1996;11:878-880.
32.
Kvaskoff M, Han J, Qureshi AA, Missmer SA: Pigmentary traits, family history of melanoma and the risk of endometriosis: a cohort study of US women. Int J Epidemiol 2014;43:255-263.
33.
Somigliana E, Viganò P, Abbiati A, et al: ‘Here comes the sun': pigmentary traits and sun habits in women with endometriosis. Hum Reprod 2010;25:728-733.
34.
Kvaskoff M, Mu F, Terry KL, et al: Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update 2015;21:500-516.
35.
Tu FF, As-Sanie S, Steege JF: Prevalence of pelvic musculoskeletal disorders in a female chronic pelvic pain clinic. J Reprod Med 2006;51:185-189.
36.
Williams RE, Hartmann KE, Sandler RS, Miller WC, Savitz LA, Steege JF: Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain. Am J Obstet Gynecol 2005;192:761-767.
37.
Slocumb JC, Kellner R, Rosenfeld RC, Pathak D: Anxiety and depression in patients with the abdominal pelvic pain syndrome. Gen Hosp Psychiatry 1989;11:48-53.
38.
Walker E, Katon W, Harrop-Griffiths J, Holm L, Russo J, Hickok LR: Relationship of chronic pelvic pain to psychiatric diagnoses and childhood sexual abuse. Am J Psychiatry 1988;145:75-80.
39.
Steege JF, Siedhoff MT: Chronic pelvic pain. Obstet Gynecol 2014;124:616-629.
40.
Schrager S, Falleroni J, Edgoose J: Evaluation and treatment of endometriosis. Am Fam Physician 2013;87:107-113.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.